Who are butyrate enemas + routine management's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/butyrate-enemas-routine-management.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

butyrate enemas + routine management — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

butyrate enemas + routine management (butyrate enemas + routine management) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Short-chain fatty acid. Area: Gastroenterology / Inflammatory Bowel Disease.

phase 3 Short-chain fatty acid GPR43 and GPR109A (butyrate receptors) Gastroenterology / Inflammatory Bowel Disease Small molecule Live · refreshed every 30 min

Target snapshot

butyrate enemas + routine management (butyrate enemas + routine management) — Assistance Publique Hopitaux De Marseille. Butyrate enemas deliver short-chain fatty acids directly to the colon to reduce inflammation and promote healing of the intestinal mucosa.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
butyrate enemas + routine management TARGET	butyrate enemas + routine management	Assistance Publique Hopitaux De Marseille	phase 3	Short-chain fatty acid	GPR43 and GPR109A (butyrate receptors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Short-chain fatty acid class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). butyrate enemas + routine management — Competitive Intelligence Brief. https://druglandscape.com/ci/butyrate-enemas-routine-management. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab